Quick Answer
CUMBERLAND PHARMACEUTICALS INC reported Research And Development Expense of $5.57 million for the year ending 2025.
- CUMBERLAND PHARMACEUTICALS INC showed an increase of +15.6% in Research And Development Expense from 2024 to 2025.
- This data is from CUMBERLAND PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), CUMBERLAND PHARMACEUTICALS INC's Research And Development Expense has grown by 11.5%.
- Historical annual values: Fiscal year 2025: $5.57 million | Fiscal year 2024: $4.82 million | Fiscal year 2023: $5.83 million | Fiscal year 2022: $6.69 million | Fiscal year 2021: $5.68 million | Fiscal year 2020: $5.77 million | Fiscal year 2019: $6.87 million | Fiscal year 2018: $7.58 million | Fiscal year 2017: $4.28 million | Fiscal year 2016: $3.19 million | Fiscal year 2015: $3.85 million | Fiscal year 2014: $3.39 million | Fiscal year 2013: $5.62 million | Fiscal year 2012: $5.10 million | Fiscal year 2011: $5.03 million | Fiscal year 2010: $4.33 million | Fiscal year 2009: $4.99 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: